ASCO 2010 - American Society of Clinical Oncology - June 2010 - Chicago
VIDEOS
Dr. Sonali Smith talks about some of the advances in chronic myeloid leukemia care coming out of the 2010 ASCO Annual Meeting.
2010 ASCO Annual Meeting Research Review Session for Patient Advocates - Session One
ARTICLES
ASCO Update: New Weapons in the Fight Against Chronic Myeloid Leukemia
August 17, 2010, Pharmacy Times
What did you get out of the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO)?
June 11, 2010, Pharmaphorum
PATIENT ASSOCIATIONS
ASCO 2010- Abstracts from the yearly meeting of the American Society of Clinical Oncology
by cmlsupport
Dr. Sonali Smith talks about some of the advances in chronic myeloid leukemia care coming out of the 2010 ASCO Annual Meeting.
2010 ASCO Annual Meeting Research Review Session for Patient Advocates - Session One
ARTICLES
ASCO Update: New Weapons in the Fight Against Chronic Myeloid Leukemia
August 17, 2010, Pharmacy Times
What did you get out of the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO)?
June 11, 2010, Pharmaphorum
PATIENT ASSOCIATIONS
ASCO 2010- Abstracts from the yearly meeting of the American Society of Clinical Oncology
by cmlsupport
SOME INTERESTING ABSTRACTS
Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.
Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM).
Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200.
Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib.
Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies.
Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.
Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib.
Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).
Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg ± IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV.
Relationship between dasatinib exposure and long-term clinical outcomes in chronic-phase chronic myeloid leukemia (CML-CP) patients.
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients.
Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: Results from ENESTnd.
The importance of imatinib dose intensity in imatinib plus combination chemotherapy in newly diagnosed Ph+ ALL.
BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies.
Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy.
BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.
Central nervous system disease and acute myeloid leukemia or chronic myeloid leukemia: Cytogenetic profile.
United States (US) practices for chronic myelogenous leukemia (CML) management compared to other countries: A worldwide observational registry.
Early intensification of imatinib treatment based on precise definition of accelerated phase in patients with chronic myeloid leukemia: Population-based analysis.
Reactivation of latent viral hepatitis infection in patients of chronic myeloid leukemia treated with imatinib mesylate: Experience from a tertiary cancer center in India.
Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib.
Meta-analysis of cord blood transplantations for indication of leukemia from private umbilical cord blood banks from 1993-2009.
Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine kinase inhibitors (TKIs).
The effect of nilotinib on major molecular responses (MMR) compared with imatinib in Japanese patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Results from the Japanese subset of ENESTnd.
Developing an economic model to estimate the cost-effectiveness of first-line treatments for chronic myelogenous leukemia.
Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study.
CPX-351: A randomized phase IIb study first-relapse patients younger than age 65.
Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.
Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM).
Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200.
Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib.
Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies.
Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.
Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib.
Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).
Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg ± IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV.
Relationship between dasatinib exposure and long-term clinical outcomes in chronic-phase chronic myeloid leukemia (CML-CP) patients.
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients.
Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: Results from ENESTnd.
The importance of imatinib dose intensity in imatinib plus combination chemotherapy in newly diagnosed Ph+ ALL.
BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies.
Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy.
BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.
Central nervous system disease and acute myeloid leukemia or chronic myeloid leukemia: Cytogenetic profile.
United States (US) practices for chronic myelogenous leukemia (CML) management compared to other countries: A worldwide observational registry.
Early intensification of imatinib treatment based on precise definition of accelerated phase in patients with chronic myeloid leukemia: Population-based analysis.
Reactivation of latent viral hepatitis infection in patients of chronic myeloid leukemia treated with imatinib mesylate: Experience from a tertiary cancer center in India.
Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib.
Meta-analysis of cord blood transplantations for indication of leukemia from private umbilical cord blood banks from 1993-2009.
Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine kinase inhibitors (TKIs).
The effect of nilotinib on major molecular responses (MMR) compared with imatinib in Japanese patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Results from the Japanese subset of ENESTnd.
Developing an economic model to estimate the cost-effectiveness of first-line treatments for chronic myelogenous leukemia.
Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study.
CPX-351: A randomized phase IIb study first-relapse patients younger than age 65.
